Healthcare is a major contributor to this planetary crisis. The Canadian Anesthesiologists’ Society (CAS) firmly believes that all efforts should be made to reduce the impact of the healthcare sector on the environment while improving the quality of care.
Read More
This document accompanies the document Greening the OR: CAS Position Statement on
reducing harmful emissions, waste and costs and provides the rationale and evidence for
CAS’ recommendations.
Read More
We have received reports from anesthesiologists in Ontario regarding coring issues when
using BD Blunt needles to draw medications. Coring involves a small piece of the rubber
stopper detaching during needle insertion, which may lead to contamination or injection of
rubber fragments into patients.
Read More
On September 29, 2024, Baxter International (Baxter US) announced that its North Cove manufacturing facility in Marion, North Carolina, was damaged by flooding caused by Hurricane Helene.1 This U.S. facility mainly manufactures intravenous and peritoneal dialysis solutions. This facility was responsible for a significant proportion of the intravenous fluids supply in the United States.
Read More
Chloroprocaine was withdrawn from the Canadian market in 2012 due to a corporate decision by its manufacturer, citing a shortage of essential raw materials needed for production. However, chloroprocaine remained in production and widely available in the United States and Europe.
Read More
Chloroprocaine was discontinued from the Canadian market in 2012, as a result of a corporate decision made by its manufacturer (in the context of a shortage of raw materials required to produce it). Chloroprocaine is still manufactured and broadly available in the United States and Europe.
Read More